Latin American Market for Heart Valve Devices Will Approach $200 Million by 2022

March 26, 2014

Transcatheter Aortic Valve Replacement Devices Will See Rapid Adoption, But Are Unlikely to Match Success Seen in US and Europe, According to Findings from Decision Resources Group

BURLINGTON, Mass., March 26, 2014 /PRNewswire/ — Decision Resources Group finds that the Latin American market for heart valve devices will approach $200 million by 2022, with rapid growth driven largely by favorable demographics and the rising adoption of transcatheter heart valve (THV) products, including transcatheter aortic valve replacement (TAVR) and transcatheter mitral valve repair (TMVR) devices. The high prices of these technologies will support double-digit revenue expansion across Argentina, Brazil, Colombia and Mexico as physicians increasingly opt for these minimally invasive technologies.


Other key findings from the Medtech 360 report entitled Latin American Markets for Heart Valve Devices 2014:

    --  Brazil and Argentina: Brazil and Argentina will see the strongest
        revenue growth through 2022; the governments of both countries have
        invested heavily in the advancement of healthcare, increasing patient
        access to procedures. This investment has also enabled more facilities
        to adopt premium-priced transcatheter heart valve technologies than in
        Mexico or Colombia.
    --  Replacement versus repair: Although adoption of heart valve repair
        devices will outpace that of replacement devices in most countries, the
        uncharacteristically low price of tissue heart valve replacement devices
        in Brazil has prevented a more significant shift to surgical repair from
    --  TMVR devices: TMVR devices will begin entering Latin American markets in
        2015. Initial uptake will be lower than in Europe or the United States
        due to lack of physician training and cost sensitivity.

Comments from Decision Resources Group Analyst Michelle Chan:

    --  "Prices of TMVR devices will drop significantly through 2022, given that
        they will enter the market at a very high price. As was the case with
        TAVR devices, price declines will begin to stabilize as TMVR becomes
        more established."
    --  "Although the market is dominated by international players, Brazilian
        competitor Braile Biomedica has captured significant market share by
        offering low prices and a broad product portfolio; the company is also
        the only local competitor that has a TAVR device."

About Decision Resources Group

Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. Clients rely on this analysis and data to make informed decisions. Find out more at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

Logo – http://photos.prnewswire.com/prnh/20130103/MM36768LOGO

For more information, contact:

Decision Resources Group

Christopher Comfort



SOURCE Decision Resources Group

Source: PR Newswire

comments powered by Disqus